Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 15/20 | 1.00 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298886 | 0.87 | HTR2B (1.00) | HTR2BUSP2JAK1SMN1; SMN2 | |
| SCHEMBL1299048 | 0.87 | HTR2B (1.00) | HTR2BUSP2 | |
| SCHEMBL1298958 | 0.86 | HTR2B (0.85) | HTR2BUSP2JAK1 | |
| SCHEMBL3811962 | 0.85 | HTR2B (0.72) | HTR2BMAPK7SMN1; SMN2 | |
| SCHEMBL1298926 | 0.84 | HTR2B (0.85) | HTR2BUSP2JAK1 | |
| SCHEMBL1299447 | 0.84 | HTR2B (0.85) | HTR2BUSP2JAK1 | |
| SCHEMBL1298775 | 0.84 | HTR2B (0.85) | HTR2BUSP2JAK1 | |
| SCHEMBL1299235 | 0.84 | HTR2B (0.78) | HTR2BUSP2SMN1; SMN2 | |
| SCHEMBL1299095 | 0.83 | HTR2B (0.72) | HTR2BUSP2SMN1; SMN2 | |
| SCHEMBL13873294 | 0.83 | SMN1; SMN2 (0.77) | HTR2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2025-06-05 | — | — | US | disclosed |
| CN-113631548-B | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220162183-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2022-05-26 | — | — | US | disclosed |
| EP-3947360-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | Zoetis Services LLC (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020198478-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2020-10-01 | — | — | WO | disclosed |
| US-8609696-B2 | Serotonin 5-HT2B receptor inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2010080357-A1 | SEROTONIN 5-HT2B RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162183-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR5A | HTR2B 1/4885MAPK7 3865/4885USP2 2460/4885 |
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR5A | HTR2B 1/4885MAPK7 3865/4885USP2 2460/4885 |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | HTR2B, HTR1B, HTR3B | HTR2B 1/4885MAPK7 2808/4885USP2 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.